The program, similar to programs carried out since 2013, clearly demonstrates the ongoing commitment of
Chief Executive Officer of
'I strongly believe along with the Board of Directors that a high employee shareholding contributes to develop a common spirit and unite our employees worldwide. This plan is a great opportunity for them to participate in the development of the company. Every year the record level of employee participation demonstrates how committed and supportive they are to
Starting
In 2021, the employee share ownership plan was open to over 90,000 employees in 73 countries with a growing overall uptake rate of 37.5% (vs 36.9% in 2020). More than 34,000
Detailed conditions
An eligibility condition of three months employment by the closing date of the offer period will apply. Eligible staff will be able to subscribe shares from
The maximum number of
The new shares, including the matching shares (the 'Shares'), will be subscribed (or delivered) either directly or through the intermediary of employee mutual funds ('FCPE'), depending on the regulations and/or tax regime applicable in the various countries of residence of those eligible for the capital increase.
The Shares will be fully fungible with the existing ordinary shares comprising the share capital of
The voting rights attached to the subscribed Shares will be exercised directly by the employees.
Those taking up this offer will be required to hold the Shares or the corresponding FCPE units for a period of approximately five years, i.e. until
Admission of the Shares to trading on the Euronext Paris market (ISIN Code: FR0000120578) on the same line as the existing shares will be requested as soon as possible after the completion of the capital increase.
This press release does not constitute an offer to sell or a solicitation to buy
More generally, the offer will only be made in countries where all required registration and/or notification procedures have been carried out, approvals obtained, and procedures for consulting or informing employee representatives followed.
This press release is not intended for and should not be copied to or distributed in countries where such a prospectus has not been approved or such exemption is not available or where all necessary registration, notification, consultation and/or information procedures have not been completed or authorisations obtained. This relates in particular to
This press release is prepared in accordance with the exemption from publication of a prospectus under Article 1 4-degreei) and 5-degreeh) of the Prospectus Regulation (
About
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Contact:
Tel: + 33 6 77 21 27 55
Email: nicolas.obrist@sanofi.com
(C) 2022 Electronic News Publishing, source